Search
Alzheimer's Disease Paid Clinical Trials in Maryland
A listing of 17 Alzheimer's Disease clinical trials in Maryland actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 17
The state of Maryland currently has 17 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including Baltimore, Bethesda, Rockville and Annapolis.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia.
The goals of this study are to learn:
* If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo
* About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
07/23/2025
Locations: Pharmasite Research, Inc. ( Site 0167), Baltimore, Maryland
Conditions: Alzheimer Disease, Dementia
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
07/22/2025
Locations: Care Access - Baltimore, Baltimore, Maryland
Conditions: Alzheimer's Disease
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
07/22/2025
Locations: CBH Health, Gaithersburg, Maryland
Conditions: Alzheimer Disease
Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)
Recruiting
CORT-X will examine if mitigation of stress-mediated pathogenesis of Alzheimer's disease (AD) is a feasible target for intervention in individuals at risk for this disease. This single-site (Baltimore, Maryland) phase II clinical trial is a 2-week, randomized, placebo-controlled crossover study of the effects of the selective glucocorticoid receptor antagonist, CORT108297, on cognitive test performance in 26 individuals with mild cognitive impairment (MCI) due to AD and in 26 cognitively normal... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/18/2025
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Memory Impairment
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Recruiting
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:
* Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
* Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
* What medical issues do participants have, if any, when taking buntanetap/Posiphen?
Researchers will compare buntanetap/Pos... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
07/17/2025
Locations: Headlands Research Pharmasite, Pikesville, Maryland
Conditions: Early Alzheimers Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Recruiting
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.
Gender:
ALL
Ages:
Between 40 years and 64 years
Trial Updated:
07/11/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
ALIGN: Aligning Medications With What Matters Most (Demonstration)
Recruiting
The goal of this clinical trial is to test the effectiveness of a pharmacist-led, primary care-based de-prescribing intervention for people living with dementia (PLWD) and the person's care partners.
The intervention consists of the following strategies: 1) a de-prescribing educational brochure designed to activate the patient and care partner; 2) a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/08/2025
Locations: Johns Hopkins Community Physicians, Baltimore, Maryland
Conditions: Polypharmacy, Alzheimer's Disease and Related Dementias, Mild Cognitive Impairment
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
06/24/2025
Locations: MD Medical Research, Oxon Hill, Maryland
Conditions: Alzheimer Disease
Clinical Trial on Agitation in Alzheimer's Dementia
Recruiting
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/09/2025
Locations: MedStar Franklin Square Medical Center Neurology, Baltimore, Maryland +2 locations
Conditions: Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression
Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease
Recruiting
Alzheimer's disease (AD) is the leading neurodegenerative disease of aging characterized by multiple cognitive impairments. Given the recent failures of disease-modifying drugs, the current focus is on preventing or mitigating synaptic damage that correlates with cognitive decline in AD patients. Transcranial Direct Current Stimulation (tDCS) is a safe, non-invasive, non-painful electrical stimulation of the brain that is shown to act as a primer at the synaptic level when administered along wit... Read More
Gender:
ALL
Ages:
Between 45 years and 85 years
Trial Updated:
05/06/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease, Logopenic Progressive Aphasia
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Recruiting
Background:
About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation.
Objective:
To learn whether COX-1 and/or COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers.
Eligibility:
Adults age 18 years and older in good general he... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
Recruiting
The goal of this clinical trial is to learn about how genetics and the response to stress predicts cognitive decline in individuals with mild cognitive impairment.
The main question\[s\] it aims to answer are:
* Does the hormone response to acute stress predict the degree of cognitive impairment following acute stress?
* Do genes associated with the risk for Alzheimer's disease influence the relationship between stress hormone response to stress and cognitive impairment following stress?
* Do... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
01/16/2025
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Mild Cognitive Impairment, Alzheimer Disease
1 - 12 of 17